Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.
about
Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expressionModes of resistance to anti-angiogenic therapyRole of sorafenib in the treatment of advanced hepatocellular carcinoma: An updateStructures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complexExciting new advances in neuro-oncology: the avenue to a cure for malignant gliomaThe Foxc2 transcription factor regulates tumor angiogenesisModulation of Autophagy by Sorafenib: Effects on Treatment ResponseVascular Wall-Resident Multipotent Stem Cells of Mesenchymal Nature within the Process of Vascular Remodeling: Cellular Basis, Clinical Relevance, and Implications for Stem Cell TherapyProfile of nintedanib in the treatment of solid tumors: the evidence to dateVascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularizationBrain tumor-targeted drug delivery strategiesTargeting angiogenesis in squamous non-small cell lung cancerSignaling pathways in the development of infantile hemangiomaClinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancerPrimary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumorAdaptation to antiangiogenic therapy in neurological tumorsFunctions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targetingFit for the Eye: Aptamers in Ocular DisordersActivity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.Sustained delivery of a HIF-1 antagonist for ocular neovascularization.Physical supports from liver cancer cells are essential for differentiation and remodeling of endothelial cells in a HepG2-HUVEC co-culture model.Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo.Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905).Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib.Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas.Platelet-derived growth factor-B normalizes micromorphology and vessel function in vascular endothelial growth factor-A-induced squamous cell carcinomasA dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo.Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma.Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Investigational agents in development for the treatment of ovarian cancerClinical impact of tumour biology in the management of gastroesophageal cancerVascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysisPhase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failureVascular-targeted photothermal therapy of an orthotopic murine glioma model.Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy.Targeting angiogenesis in advanced cervical cancer.Targeting the PDGF signaling pathway in tumor treatmentSimultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.
P2860
Q24595357-441B9F79-7ADB-4D10-A7E3-2A15BA2D5AAEQ24608005-605C6EE6-97CE-4703-8B4D-63C814AEE277Q24619987-E1491D45-65CB-4744-989C-0A4C657425FCQ24623888-E6E6B5EE-0590-489A-9362-9490371F4D51Q24632791-59E418E6-F14C-43EE-A179-B20FEAFDE186Q24647592-DE0F21A8-218A-4975-A353-48EA980216BAQ26745320-70EF4448-07D6-4469-9314-DE153D8B3394Q26765919-41B48EA8-8B4C-41BB-A34B-35452D2792A5Q26775134-C1478CF5-BF93-4F2D-A163-18D0523278FAQ26781833-95458602-3D58-4F2C-A455-3C7F51D6341BQ26829741-315B9A11-ADEE-4594-872B-3CAE41033119Q26861341-34EE9F4F-BA4C-4833-AAB2-D796DDB0B7B7Q26996608-3823E4A2-7484-4589-8E06-99D13532F814Q27024235-F0E6A5B9-4EA8-4AAC-A3F2-4ABF774409E7Q27851455-89BC65D1-A12D-492B-9D93-28BEAAE2B0D5Q28082908-5BB5DAB6-44A3-4535-9168-0A1F6E95EDCEQ28755868-B093FB54-687E-4EFF-8347-81BAF3B809B7Q28828283-1DE42AD3-8521-4DF2-AFFC-6A37B2E32E80Q30429122-804AD17E-EF33-4E3A-A826-EFADA314F03CQ30560557-4080AAB9-5683-40E0-94E6-70A2027A3D3BQ30653607-5C594213-CEEC-4AC1-9173-9957408C3DD6Q33279184-3492206E-DD2C-4029-AC75-38D3746433F6Q33442594-0C248857-FE35-4F9E-BD1B-FFB56E385054Q33457195-5EA9F13A-2CE9-4989-97C6-F6104BD4BE99Q33563488-B8077488-5E6D-44F3-B2C9-3D74FC73093CQ33587106-7EA6C9C1-6C86-4D15-AA98-AC5FC21C1AB8Q33597254-5F3E3FE5-137E-4D7D-A129-01DE5E4D873AQ33688219-56535EE8-EA7D-4422-B7DF-F5C830DFF4F3Q33730122-DED04C1C-046A-4626-8749-FF4F3AC17743Q33732486-5EBC64D5-0516-4E81-B2FE-00B9888F3515Q33770680-2958CB1D-EC2B-47D2-A782-6076A35DE363Q33920800-0BC15654-53EB-43D4-ACCD-455DAD9E4EF2Q33922534-BC053AB0-9D59-4C94-AB8A-7677247AE3E7Q33926377-277AC045-C2FC-4E42-AFF2-04157F435495Q34206601-8F5F25F4-E2F5-426A-A509-24DB5E17DF81Q34268162-FE2FEC8E-90DB-4C32-A675-D424AE2DCB77Q34343317-B874256D-CD67-4062-9994-FCBB5AECC8ACQ34389368-09647A34-7D2F-4C30-82AA-F391F30A04E5Q34393461-6FD9A8CD-6CB3-43F1-B953-64999652DB46Q34589774-58EB9029-5DA0-4310-85A3-EB9EE18263C5
P2860
Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Combined inhibition of VEGF an ...... lial cell survival mechanisms.
@en
Combined inhibition of VEGF an ...... lial cell survival mechanisms.
@nl
type
label
Combined inhibition of VEGF an ...... lial cell survival mechanisms.
@en
Combined inhibition of VEGF an ...... lial cell survival mechanisms.
@nl
prefLabel
Combined inhibition of VEGF an ...... lial cell survival mechanisms.
@en
Combined inhibition of VEGF an ...... lial cell survival mechanisms.
@nl
P2093
P356
P1433
P1476
Combined inhibition of VEGF an ...... lial cell survival mechanisms.
@en
P2093
Alice D Katsen
Andreas Thurnher
Axel Ullrich
Gesine Groth
Hans-Peter Hammes
Heinz Kerger
Michael D Menger
Peter Vajkoczy
Ralf Erber
P304
P356
10.1096/FJ.03-0271FJE
P407
P577
2003-12-04T00:00:00Z